Modulation of g protein signaling normalizes tumor vessels

Mitali Manzur1, Juliana Hamzah, Ruth Ganss

  • 1Western Australian Institute for Medical Research, The University of Western Australia Centre for Medical Research, Perth, Western Australia, Australia.

Cancer Research
|January 17, 2009
PubMed

Insights

Regulators of G protein signaling 5 (RGS5) influence tumor blood vessel development. Removing RGS5 normalizes tumor vessels, improving blood flow and enhancing anti-tumor immunotherapy effectiveness.

Area of Science:

  • Molecular biology
  • Cancer research
  • Immunology

Background:

  • G protein-coupled biological processes are implicated in numerous human diseases.
  • Regulators of G protein signaling (RGS) are crucial accessory molecules for fine-tuning these processes.
  • RGS5, a marker for tumor-resident pericytes, is vital in vascular maturation and remodeling during cancer development.

Purpose of the Study:

  • To investigate the role of RGS5 in tumor vascularization and its impact on anti-tumor immunity.
  • To explore the therapeutic potential of targeting RGS5 for improving cancer treatments.

Main Methods:

  • Analysis of tumor morphology and blood flow in RGS5-deficient models.
  • Assessment of lymphocyte infiltration and response to immunotherapy in RGS5-deficient tumors.

Main Results:

  • Tumors in RGS5-deficient backgrounds exhibit normalized vessel morphology.
  • RGS5 deficiency leads to improved blood flow within tumors.
  • These vascular changes significantly enhance lymphocyte access and the efficacy of anti-tumor immunotherapy.

Conclusions:

  • RGS5 plays a critical role in regulating tumor angiogenesis and vascular remodeling.
  • Targeting RGS5 presents a promising strategy for enhancing the effectiveness of anti-cancer therapies, particularly immunotherapy.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...